Novo Nordisk and Eli Lilly are competing in the development of weight loss drugs, with recent trials and studies yielding mixed results. Some findings suggest Novo Nordisk's drug may have advantages in preserving lean body mass, while others indicate Eli Lilly's drug has shown promise in Phase 3 trials. The outcome of the competition between the two companies remains uncertain, with varying assessments of their relative strengths and weaknesses.